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peritoneal malignant mesothelioma
Hakan Alakus1,3,4, Shawn E Yost2, Brian Woo3, Randall French4, Grace Y Lin5, Kristen Jepsen6, Kelly A Frazer2,3,6*,
Andrew M Lowy3,4* and Olivier Harismendy3,7*Abstract
Background: Malignant mesothelioma (MM) arises from mesothelial cells that line the pleural, peritoneal and
pericardial surfaces. The majority of MMs are pleural and have been associated with asbestos exposure. Previously,
pleural MMs have been genetically characterized by the loss of BAP1 (40-60%) as well as loss of NF2 (75%) and
CDKN2A (60%). The rare peritoneal form of MM occurs in ~10% cases. With only ~300 cases diagnosed in the
US per year, its link to asbestos exposure is not clear and its mutational landscape unknown.
Methods: We analyzed the somatic mutational landscape of 12 peritoneal MM of epitheloid subtype using copy
number analysis (N = 9), whole exome sequencing (N = 7) and targeted sequencing (N = 12).
Results: Peritoneal MM display few copy number alterations, with most samples having less than 10 Mbp total
changes, mostly through deletions and no high copy number amplification. Chromosome band 3p21 encoding
BAP1 is the most recurrently deleted region (5/9), while, in contrast to pleural MM, NF2 and CDKN2A are not
affected. We further identified 87 non-silent mutations across 7 sequenced tumors, with a median of 8 mutated
genes per tumor, resulting in a very low mutation rate (median 1.3 10−6). BAP1 was the only recurrently mutated
gene (N = 3/7). In one additional case, loss of the entire chromosome 3 leaves a non-functional copy of BAP1
carrying a rare nonsense germline variant, thus suggesting a potential genetic predisposition in this patient.
Finally, with targeted sequencing of BAP1 in 3 additional cases, we conclude that BAP1 is frequently altered
through copy number losses (N = 3/12), mutations (N = 3/12) or both (N = 2/12) sometimes at a sub-clonal level.
Conclusion: Our findings suggest a major role for BAP1 in peritoneal MM susceptibility and oncogenesis and
indicate important molecular differences to pleural MM as well as potential strategies for therapy and prevention.
Keywords: Genomics, Mutations, Tumor Suppressor, Peritoneal, MesotheliomaBackground
Malignant mesothelioma (MM) is an aggressive tumor,
which arises from mesothelial cells that line the pleural,
peritoneal and pericardial surfaces [1]. The age-adjusted
incidence of MM in the USA is about 1 per 100,000 [2].
The majority of MM cases are caused by asbestos or
erionite exposure with a latency of typically 20–40 years
from exposure to diagnosis. MM is highly resistant to
conventional cytotoxic therapies and no active molecularly* Correspondence: kafrazer@ucsd.edu; alowy@ucsd.edu; oharismendy@ucsd.edu
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unless otherwise stated.targeted agents have been identified. As the disease is
typically identified late in its course, most patients usually
die within 2 years of diagnosis with a total of ~3,000
deaths in the US per year [3,4]. One of the largest studies
to date screened 53 primary pleural MM for genome-wide
copy-number-aberrations (CNAs) and performed targeted
sequencing of selected potential driver genes from the
recurrent CNAs [5]. The majority of samples showed
recurrent losses of 9p21, 22q and 3p21. BRCA1 associated
protein-1 (BAP1) located at the epicenter of 3p21.1 was
inactivated by somatic alterations in 42% of all tumors.
This study also confirmed findings from previous reports,
showing that CDKN2A (9p21) and NF2 (22q) are inacti-
vated in ~60% and 75% of pleural MM respectively [6-10].
Finally other genes have been shown to be mutated in aThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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associated with activation of the YAP pathway [11].
While most studies have focused on pleural MM, about
one in ten cases of MM arises from the peritoneum, which
makes it an extremely rare condition (incidence ~1 per mil-
lion in the U.S) and to our knowledge, the largest molecular
study to date included only 6 cases [12]. In contrast to
pleural MM, about 50% of peritoneal MMs do not have a
clear history of asbestos exposure [13] and it is still
unknown whether MMs from different sites of origin
(pleural, peritoneal or pericardial) share genomic alterations
or undergo similar oncogenic transformations [14-16].
Moreover, while whole exome sequencing has been applied
to multiple common and rare tumors, it has never been
used to determine the genome-wide mutational landscape
of MM. Thus we sought to study the mutations present in
peritoneal MM using a combination of whole exome
sequencing (mutations), copy number arrays (CNA) or tar-
geted sequencing. Examining 12 unique cases of epithelioid
peritoneal mesothelioma, we identified the most recurrent
somatic events present in this malignancy and compare the
findings with what is known about pleural mesothelioma.
Methods
Samples and histology
The acquisition and use of peritoneal MM samples was
approved by the Institutional Review Board of the
University of California, San Diego. Before enrolling in
the study, patients gave informed consent. Blood sam-
ples for germline DNA extraction were collected before
and tumor samples were collected during surgical tumor
resection. The resected tumor samples were fixed in
10% formalin, embedded in paraffin and H&E-stained
for evaluation by a surgical pathologist. Smaller parts of
each tumor were put into 2x2x2 cm wells (Tissue Tek,
Miles Scientific), covered with OCT and flash frozen.
These samples were used for isolation of tumor DNA
after cryosectioning, H&E-staining and evaluation for
tumor cell content. Histologic examination of cases of
mesothelioma may show many morphologic patterns
and variable degrees of cytomorphologic atypia. The main
histologic subtypes include epithelioid and sarcomatoid.
Our study is limited to the epithelioid subtype. Genomic
DNA was extracted from tumor samples with ≥ 70%
tumor cell content using the AllPrep® DNA/RNA/miRNA
kit (Qiagen®) and germline DNA was extracted from
100 μl buffy coats with the DNeasy Blood and Tissue kit
(Qiagen®) according to the manufacturer’s instructions.
DNA concentration was determined by fluorometry (Qubit®,
Life Technologies).
Exome capture and library preparation
The sequencing libraries were prepared and captured using
SureSelect Human All Exon V4 kit (Agilent Technologies)following the manufacturer’s instructions. Briefly, 500 ng
DNA was fragmented by Adaptive Focused Acoustics
(E220 Focused Ultrasonicator, Covaris, Woburn,
Massachusetts) to produce an average fragment size
of ~175 base pairs. Fragmented DNA was purified
using the Agencourt AMPure XP beads (Beckman
Coulter, Fullerton, CA, USA). The quality of the
fragmentation and purification was assessed with the
Agilent 2100 Bioanalyzer. The fragment ends were
repaired and adaptors were ligated to the fragments.
The resulting DNA library was amplified by using
manufacturer’s recommended PCR conditions: 2′ at
98°C followed by 6 cycles of (98°C 30”; 65°C 30”; 72°C 1’)
finished by 10’ at 72°C. 500 ng of each library was
captured by solution hybridization to biotinylated RNA
library baits for 48 hrs at 65°C. Bound genomic DNA was
purified with streptavidin coated magnetic Dynabeads
(Invitrogen, Carlsbad, CA) and further amplified to add
barcoding adapters using manufacturer’s recommended
PCR conditions: 2′ at 98°C followed by 12 cycles of (98°C
30”; 57°C 30”; 72°C 1′) finished by 10′ at 72°C.
Exome sequencing and analysis
Sequencing was performed using the Illumina HiSeq
2000 system, generating 100 bp paired-end reads. All
raw 100 bp paired-end reads were aligned to the human
genome reference sequence (hg19) using BWA v0.5.9-r16
[17] with default parameters for paired-end reads except for
seed length set to 35. Aligned reads were realigned using
GATK’s [18] IndelRealigner v 1.6-5-g557da77 combining all
reads from the same patients and subsequently splitting
them. Duplicate reads were removed using Picard Tools v
1.65 MarkDuplicates. Finally the GATK’s TableRecalibration
tool was used to recalibrate the reads’ base quality scores.
Additional file 1: Table S1 presents the summary statistics
of the sequencing. The sequencing data is publically
available via the NCBI Short Read Archive (SRA067608).
We used VarScan2 v 2.3 [19] to compare the tumor to the
normal sample and identify, for each patient, single
nucleotide variants (SNVs) and small insertions and dele-
tions (indels) that are: 1) inherited (germline variants);
2) acquired in the tumor (somatic mutations) as well
as variants resulting from a loss of heterozygosity
(LOH) or of unknown status. The required pileup
files for VarScan2 were generated using SAMTools
[20] mpileup v 0.1.18 with default parameters except
for –q 5, −Q 0, −d 50000, and -B. We used the default
parameters for filtering variants except changing the
tumor, normal, and combined minimum coverage to 10X
each, minimum mutant allele frequency of 0.1, and
minimum average quality score to 17. We then applied
additional filtering steps. 1) Low quality indels: somatic
indels with <10X coverage depth or fewer than 3 supporting
reads or with more than 5% frequency in the germline
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3 bp of an indel, 2b) clustering SNV: ≥3 SNVs located
within 10 bp, 2c) less than 10% allelic frequency. 3) Low
quality somatic variants: Somatic variants with Varscan
Fisher p-value < 0.05 or with >5% alternate allele in the
normal DNA (SNVs) or any alternate allele in the normal
(indels) are filtered. 4) VarScan2 high quality filter:
We finally applied VarScan2’s fpfilter script to both
germline and somatic variants. This procedure filters
variants based on their read position, strand bias, variant
reads, variant frequency, distance to 3′, homopolymer,
mapping quality difference, read length difference, and
mismatch quality sum difference. Variants were queried
against dbSNP135 to determine novel or known variants.
Next we used snpEff [21] v. 2.0.5 or ANNOVAR [version
2014-07-14] [22] to identify the different the functional
and impact on coding genes.
Illumina exome array and copy number analysis
The tumor DNA from 9 cases was analyzed on the
Illumina CoreExome Array. For our analysis, we uti-
lized the Genotyping module (1.9.4) within Illumina’s
GenomeStudio (GS) V2011.1. Data was normalized
using default parameters and Log R Ratios and B Allele
Frequencies were exported for further analysis in R.
Because the platform is designed to detect additional rare
variants that may interfere with CNA analysis, we used
only the probes found on Illumina’s HumanCore
BeadChip, which is dedicated to Copy Number Analysis,
and excluded the rare variants designed from the human
exome. We removed probes with missing values for any of
the samples. To perform segmentation analysis, we used
the copynumber package from Bioconductor using default
parameters. For analysis purposes, we assigned a segment
with a LogR ratio greater than 0.25 as being an amplified
region and a LogR ratio less than −0.25 as being a deleted
region. Due to the normalization procedure, chromosome
3 aneuploidy in sample AA2463T was only identified by
manual review and added to the segmentation results. A
cytoband was called deleted (respectively amplified)
when more than 75% of its length belonged to a deleted
(resp. amplified) segment.
BAP1 targeted sequencing and PCR amplification
We used Illumina TruSeq custom amplicons panel. We
used DesignStudio (Illumina, Inc San Diego CA) to design
custom primers to amplify all exons in BAP1. Following
the manufacturer’s recommendation we used the DNA
from 12 fresh frozen tumor specimens and matched
blood DNA from 2 patients to amplify the targets
using 14 multiplexing primers. After purification and
quantification, we combined the 14 libraries in equi-
molar amounts and sequenced them using Illumina
MiSeq sequencer for 2x150 bp reads. The sequencingreads were then aligned and mutation called using the
Illumina BaseSpace cloud with TruSeq DNA amplicon
application or using Mutascope locally [23]. To increase the
detection sensitivity the reads spanning the expected 42 nt
deletion in AA2476T tumor were aligned independently
using BLAT [24]. To analyze the large deletion in sample
AA2476T we performed the PCR amplification using the
following primers: BAP142delF: AGCCAGCATGGAGA
TAAAGG and BAP142delR TGCCTCAAGGAGGAGG
TAGA. The results of the analysis of the BAP1 mutation in
AA2476T are presented in Additional file 2: Figure S1.
Results and discussion
To date, most genome-wide analysis of MM have used
copy number (or CGH) arrays to identify potentially
recurrent chromosomal alterations in the tumors. We
analyzed 9 tumors using the Illumina CoreExome arrays,
identifying high confidence copy number segments. We
observed that 3/9 tumors had no large copy number
events, while 3/9 had between 1 and 6 large copy
number events, and the remaining 3 had between 14
and 95 segments with a maximum of 290 Mb net
copy number changes, including the loss of chromosome 3
in one tumor (Figure 1A – Additional file 1: Table S2).
About 14/82 deleted segments also show evidence of a loss
of heterozygosity (B Allele Frequency > 0.55), increasing
our confidence in these calls. There were no detectable
copy number gains recurring in more than 2 samples
across the 9 tumors analyzed and none of them were
high-level amplifications (max LogR = 0.55). We identi-
fied five cytobands where copy number losses or strong
loss of heterozygosity are present in 3 or more samples
(Additional file 1: Table S3): 12q24.13 (N = 4), 3p21 (N = 3)
and 3p14 (N = 3), 15q15.3 (N = 3) and 15q21.1 (N = 3). An
analysis of the 369 genes located in these regions reveals
that 3p21 harbors the most significantly affected genes,
with the lowest net loss (sum of log ratio across all
samples) and highest net LOH (Figure 1B). Among those,
BAP1 and PBRM1, located 135 kb apart, are known
tumor suppressors in pleural MM [5] and renal clear
cell carcinoma [25] respectively. At the resolution
permitted by our analysis, we did not identify other
significant copy number alterations. In particular NF2
(22q) and CDKN2A (9p21), known to be frequently lost in
pleural MM do not exhibit any copy number alterations
in peritoneal MM (Additional file 2: Figures S3-S4). Over-
all these results suggest that peritoneal MM exhibits few
copy number alterations, mostly losses, and that BAP1
and its neighboring genes on 3p21 are lost in 5/9 tumors
(Additional file 2: Figure S2).
We next performed whole exome sequencing on 7 out
of the 9 tumors for which matched normal DNA was
available and called somatic mutations in all 7 tumors
(Additional file 1: Table S4). We were able to identify
Figure 1 Copy number alterations in 9 peritoneal MM tumors. (A) The cumulative number of base pairs affected by losses (blue) or gains (red) in
large segments (>1 Mb) is indicated for each tumor. The corresponding number of segments (Lost/Gained) is mentioned next to the sample ID.
(B) Net Log Ratio (x axis) and B allele frequency (y axis) calculated across all 9 tumors for 369 genes located in the 5 recurrently lost cytobands.
3p21 (red genes) shows the strongest net loss (x axis) and net LoH (y axis). The data points corresponding to PBRM1 and BAP1 genes are labeled.
(*) the BAP1 data point overlaps with other genes located in the same segment.
Figure 2 Somatic mutations in 7 peritoneal MM cases. The total
number of somatic mutations as well as their predicted effect
is represented.
Alakus et al. Journal of Translational Medicine  (2015) 13:122 Page 4 of 7between 47 and 133 mutations per tumor, of which 2 to
33 are non-silent (Figure 2). With a median of 1.3 muta-
tions per million base pairs, peritoneal MM has a much
lower mutation rate than other adult solid tumors, and
comparable to pediatric cancers, leukemias or endocrine
cancers [26]. Across all seven cases, 87 somatic muta-
tions were affecting the coding region of 83 genes
(Additional file 1: Table S5). BAP1 was the only
recurrently mutated gene, affecting 3 tumors through
2 nonsense mutations and one 42 nt frameshift. The
BAP1-K453* mutation has an allelic fraction of 48% in a
tumor without BAP1 loss (AA2273T), indicating that one
WT copy remains. Similarly, BAP1-Q393* is identified in
12% of the sequencing reads consistent with the genetic
heterogeneity of this tumor where a subclonal loss of 3p21
was observed (AA1844T - Additional file 2: Figure S2).
Finally BAP1-I71fs was identified in only 14% of the se-
quencing reads in a tumor with BAP1 LOH (AA2476T).
The unusual length of the deletion (42 nt) may have
prevented additional reads from aligning to the reference
genome resulting in an underestimation of the allelic frac-
tion. Alternatively, both loss and mutations in this tumor
may occur at a sub-clonal level. Overall, our results suggest
that BAP1 is affected by concurrent copy number loss and
mutations (2/7), mutation only (1/7) or loss only (3/7).
With the paired sequencing of tumor and normal
DNA, we are able to distinguish with confidence
germline variants from somatic mutations. In particular, we
identified a loss of function variant in BAP1 (BAP1-Y44*) in
the germline DNA of one patient (AA2463T). This patient’s
tumor was also characterized by the loss of chromosome 3.
The Y44* variant has not been identified in the
NHLBI Exome Sequencing Project [27] nor by the Exome
Aggregation Consortium [28] and may thus have a minorallele frequency of less than 10−5, or be a de novo acquired
variant in this patient. Inherited loss of function variants
in BAP1 are known to increase susceptibility to melan-
oma, renal cell carcinomas and malignant mesothelioma
[29-31]. A more detailed evaluation of this patient’s family
Alakus et al. Journal of Translational Medicine  (2015) 13:122 Page 5 of 7history would however be necessary to establish the true
genetic risk associated with this nonsense variant.
To further establish the prevalence of somatic mutations
in peritoneal MM, we performed targeted sequencing of
BAP1 exons in 12 tumors, including 3 cases not evaluated
by exome or copy number analysis. This analysis allows us
to confidently call mutations at high coverage depth.
Across all exons and samples, greater than 91% of BAP1
coding base pairs were covered by 100 reads or more. We
were able to confirm in three samples the presence of
BAP1-Q393*, K453* and I71fs at an allelic fraction of 20%,
51% and 20% respectively, consistent with the whole
exome sequencing findings (Additional file 1: Table S6).
We find additional BAP1 somatic mutations in two
samples: at Q684* (50% allelic fraction) and A95fs
(39% allelic fraction). In summary, BAP1 is the most
altered gene in peritoneal MM (Table 1), affecting 66%
(8/12) of the studied cases through somatic mutations
(N = 3), allelic copy number loss (N = 3), or both (N = 2).
Peritoneal MM is an extremely rare malignancy and,
in contrast to pleural MM, has never been analyzed on a
genome-wide scale before. Early cytogenetic and loss of
heterozygosity (LOH) analyses of pleural MMs described
deletions as the most common cytogenetic aberration,
suggesting that the inactivation of tumor suppressor
genes residing in these deleted chromosomal regions
may be responsible for neoplastic transformation [32].
Losses of 3p21 were described as a common alteration
(13/23, 57%) in pleural MM twenty years ago [33] and in
a recent study, the BAP1 tumor suppressor gene at 3p21
was frequently affected by loss, mutations or both
(22/53; 42%). It has therefore been concluded that
BAP1 loss drives the selection for 3p21 deletions inTable 1 BAP1 genetic status (germline or somatic) across
all 12 cases
Sample Assay1 BAP1
Germline LOH Somatic (Allelic Fraction)
AA1844T A + E + T subclonal Q393* (E:12%, T:20%)
AA1968T A + E + T
AA2273T A + E + T K453* (E:48%, T:51%)
AA2463T A + E + T Y44* chr3
AA2476T A + E + T 15 Mb I71fs (E:14%, T:20%)
AA2528T A + E + T
AA2253T A + E + T 0.34 Mb
AA2489T A + T 54 Mb
AA2617T A + T NA A95fs (39%)
AA2830T T NA NA
AA2627T T NA NA Q684* (50%)
AA2819T T NA NA
1: A: copy number array; E: whole exome sequencing; T: targeted sequencing.pleural MM [4]. Furthermore, germline mutations of
BAP1 in two families have also been shown to predispose
to pleural MM [29] and heterozygous BAP1−/+ mice are
more susceptible to mesothelioma than their wild type
littermate [34] thus strongly implicating BAP1 as a central
player in MM tumorigenesis,.
Here we report that somatic alterations in 3p21 are
also present in the majority of peritoneal MM. Five samples
revealed deletions at 3p21 resulting in loss of one or two
cancer genes (BAP1 and/or PBRM1) per sample. Further
investigation by whole exome and targeted sequencing
suggests that BAP1 is the most significant gene in this
region as it is recurrently altered by somatic loss of function
mutations in 5 tumors. While BAP1 is a natural candidate
driver in 3p21 given its somatic alterations in pleural MM,
PBRM1 is another potential tumor suppressor in the
region. Frequent inactivation PBRM1 by somatic alterations
have been described for kidney clear cell carcinoma
(92/227, 42%) based on exome sequencing of 7 and
targeted sequencing of 257 tumor samples [35]. However
in our study PBRM1 is recurrently lost in 6 peritoneal
MM cases but we did not identify any somatic mutations
in the 7 samples sequenced. Thus, PBRM1 is less likely to
be the most relevant gene in 3p21, except perhaps in
tumor AA1968T where the 3p21 deletion specifically
affects PBRM1 and not BAP1.
Beyond BAP1, it is important to determine which
other genes or pathways may be involved in peritoneal
MM. Surprisingly, while somatic alterations of NF2
(39/53, 74%) and CDKN2A (31/53, 58%) are common
in pleural MM [5], they are not observed in any of the 12
peritoneal MM cases we evaluated, despite adequate
coverage depth (Additional file 1: Table S7). This suggests
an important molecular difference between pleural and
peritoneal MM. A recent study demonstrated that, in
contrast to wild-type animals, CDKN2A loss is not
required for tumorigenesis in BAP1+/− mice, They further
demonstrated that BAP1 mediates Rb1 expression loss via
epigenetic down-regulation independent of CDKN2A
status [34]. This observation may imply differences in the
pathogenesis of pleural vs peritoneal MM in which the
prevalence of CDKN2A loss differs. In our study, only one
case of peritoneal MM had a clear loss of function of both
BAP1 alleles, harboring both a chromosome 3 deletion
and a germline nonsense variant. In all other cases, one
wild type copy of BAP1 likely remains or the somatic
alterations are only present at a sub-clonal level. Thus,
while the mouse model may recapitulate a typical tumor
suppressor loss pattern, with one inherited variant
and one subsequent somatic loss, it appears that alteration
or loss of the second allele may not be required in the
majority of sporadic peritoneal MMs. Rather, the presence
of a wild type allele in most studied cases, suggests that
BAP1 haplo-insufficiency may lead to peritoneal MM. The
Alakus et al. Journal of Translational Medicine  (2015) 13:122 Page 6 of 7analysis of more samples would be required to correlate
somatic BAP1 ploidy, somatic status, Rb1 expression and
epigenetic landscape with known clinical and environ-
mental features.
BAP1 is ubiquitously expressed, and involved in
multiple processes such as transcriptional regulation,
chromatin remodeling or BRCA1 mediated mismatch
repair [36]. It may be feasible to exploit BAP1 loss of
function in MM using synthetic lethal approaches
with PARP inhibitors or HDAC inhibitors for example
to leverage a potential defect in DNA repair or chro-
matin remodeling, respectively. This is a hypothesis
that remains untested at this time. However a more
systematic investigation of BAP1 partners and targets
will likely be required to reveal effective ways to target
BAP1 loss in MM.Conclusion
In conclusion, our report suggests that the loss of BAP1
is a molecular alteration characteristic of peritoneal
MM, occurring in the absence of any other strong
recognized oncogenic drivers. Inactivation of BAP1
was previously identified as a common event in pleural
MM but had never been described in peritoneal MM
before. The lack of alterations in NF2 and CDKN2A
supports the idea of distinct genomic features between
pleural and peritoneal MM. Further studies with more
samples will be required to determine the molecular
consequences and potential association with clinical
and environmental features.Additional files
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